Mitochondrial NADK, a Novel Functional Mediator of Tau Toxicity in Alzheimer's Disease
Andrés Norambuena

TL;DR
This paper commemorates 50 years of tau research in Alzheimer's disease and highlights recent advances in understanding tau's role and potential therapies.
Contribution
The paper introduces mitochondrial NADK as a novel functional mediator of tau toxicity in Alzheimer's disease.
Findings
Tau's role in microtubule polymerization was first described in 1975.
Tau is now known to be central to Alzheimer's disease pathology.
The session highlights recent advances in tau research and therapeutic strategies.
Abstract
Tau was first described in a 1975 PNAS paper from Marc Kirschner's lab as a brain protein that stimulates the polymerization of tubulin into microtubules (https://doi.org/10.1073/pnas.72.5.1858). Unbeknown at that time was the fact that tau is the building block of neurofibrillary tangles, and a central player in the pathogenesis of Alzheimer's disease (AD) and the numerous non‐Alzheimer's tauopathies. Tau's discovery thus serves as a textbook example of how advances in basic science lie at the foundation of clinical medicine. To commemorate the 50th anniversary of the first publication about tau, this Featured Research Session will highlight the work of 6 speakers, spanning basic to clinical scientists, and those who bridge the gap between these opposite, but complementary ends of the AD research community. The talks will cover major advances in tau research and how they have…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAlzheimer's disease research and treatments · Cholinesterase and Neurodegenerative Diseases · Neurological Disease Mechanisms and Treatments
